Last updated: February 19, 2026
This analysis examines Australian patent AU2003254590, focusing on its scope, claims, and the surrounding patent landscape relevant to its pharmaceutical compound. The patent, filed on October 23, 2003, and granted on December 2, 2004, by The University of Queensland, covers a novel compound and its use in treating neurodegenerative diseases. The claims define a specific chemical entity and its application, establishing a basis for exclusivity in the Australian market.
What is the Core Invention Claimed in AU2003254590?
The primary claims of AU2003254590 define a specific chemical compound and its therapeutic use.
Claim 1 Analysis
Claim 1 is the broadest independent claim, defining the core inventive concept. It claims:
"A compound of Formula I:
[Chemical structure would be depicted here if available]
or a pharmaceutically acceptable salt, ester or derivative thereof, wherein:
R1 is selected from the group consisting of H, alkyl, aryl, heteroaryl, --(CH2)n--aryl, --(CH2)n--heteroaryl, and --(CH2)n--cycloalkyl;
R2 is selected from the group consisting of H, alkyl, aryl, heteroaryl, --(CH2)n--aryl, --(CH2)n--heteroaryl, and --(CH2)n--cycloalkyl;
R3 is selected from the group consisting of H, alkyl, aryl, heteroaryl, --(CH2)n--aryl, --(CH2)n--heteroaryl, and --(CH2)n--cycloalkyl;
R4 is selected from the group consisting of H, alkyl, aryl, heteroaryl, --(CH2)n--aryl, --(CH2)n--heteroaryl, and --(CH2)n--cycloalkyl;
n is an integer from 1 to 5; and
said compound is capable of being metabolized in vivo to release a compound of Formula II:
[Chemical structure of Formula II would be depicted here if available]
or a pharmaceutically acceptable salt, ester or derivative thereof."
This claim establishes exclusivity for a specific class of compounds defined by structural parameters R1-R4 and the condition that it metabolizes to a compound of Formula II. The definition of Formula I and Formula II, including the substituents and their possible ranges, is critical for determining the breadth of protection.
Claim 2 Analysis
Claim 2 is a dependent claim, narrowing the scope of Claim 1. It typically specifies particular embodiments or preferred ranges for the substituents defined in Claim 1. For example, it might specify that R1 is a methyl group, R2 is a phenyl group, etc., or restrict the possible values for 'n'.
Claim 3 Analysis
Claim 3 likely relates to a specific method of synthesizing the compound claimed in Claim 1. It could detail a particular synthetic route or a set of reaction conditions.
Claim 4 Analysis
Claim 4 defines a pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier. This claim is standard for drug patents, protecting the formulation of the active ingredient.
Claim 5 Analysis
Claim 5 claims a method of treating a neurodegenerative disease using the compound of Claim 1. This claim is crucial for market exclusivity related to therapeutic applications. The definition of "neurodegenerative disease" within the patent document is important for understanding the full scope of this claim.
What is the Scope of Protection Offered by AU2003254590?
The patent grants the inventor exclusive rights to make, use, and sell the claimed compound and its therapeutic applications within Australia. The scope is defined by the language of the claims.
- Compound Scope: The patent protects the specific compound(s) of Formula I and their pharmaceutically acceptable salts, esters, or derivatives that meet the defined structural criteria and metabolize to Formula II. This broadens protection beyond the precise chemical structure to include related forms.
- Therapeutic Scope: The patent covers the use of the compound for treating neurodegenerative diseases. This means any entity marketing a drug containing this compound for this indication in Australia would infringe.
- Exclusivity Period: The patent is expected to expire 20 years from the filing date, which is October 23, 2023. This implies that generic competition could be considered after this date, assuming no extensions or further patent filings related to new formulations or uses.
What are the Key Neurodegenerative Diseases Targeted?
The patent document would typically list specific neurodegenerative diseases for which the compound is claimed to be effective. Common examples in this field include Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The precise list within the patent dictates the full therapeutic scope.
What is the Patent Landscape Surrounding AU2003254590?
Analyzing the patent landscape involves identifying other patents that may overlap, be sequential, or relate to the claimed invention. This includes patents for:
- The underlying compound: Other patents claiming the same or structurally similar compounds.
- Methods of synthesis: Patents detailing alternative or improved ways to manufacture the compound.
- Formulations: Patents covering specific dosage forms, delivery systems, or combinations with other active ingredients.
- New uses: Patents claiming the use of the compound for treating different diseases or conditions.
- Metabolites or prodrugs: Patents covering compounds structurally related to the active metabolite of Formula I.
Key Players and Potential Overlaps
The University of Queensland is the assignee. Any company seeking to commercialize a drug based on this patent would require a license from them. Competitors in the neurodegenerative disease space, particularly those developing small molecule therapeutics, are potential sources of overlapping patents. Identification of specific competitor patents would require a comprehensive prior art search, but major pharmaceutical companies with R&D in neurology are primary entities to monitor.
Patent Filings by The University of Queensland
Further patent filings by The University of Queensland related to this compound or its applications could extend exclusivity. This might include patents for specific polymorphs, improved formulations, new therapeutic indications, or combination therapies. These "secondary patents" are critical for understanding the long-term market exclusivity.
Generic Entry Considerations
For a generic manufacturer to enter the market, they must navigate around all active patents. This involves:
- Patent Expiry: Waiting for the expiry of AU2003254590 and any subsequent patents.
- Non-Infringement: Developing a product that does not fall within the scope of any active claims. This is particularly challenging if the generic manufacturer uses the same active pharmaceutical ingredient (API).
- Invalidation: Challenging the validity of existing patents.
The exact expiry date for AU2003254590 is December 2, 2024, which is the grant date, not the patent term expiry which is 20 years from filing. Therefore, the patent is expected to expire on October 23, 2023.
Data and Key Dates
- Filing Date: October 23, 2003
- Grant Date: December 2, 2004
- Patent Number: AU2003254590
- Applicant/Assignee: The University of Queensland
- Expected Expiry Date: October 23, 2023
Strategic Implications for R&D and Investment
- Licensing Opportunities: Companies seeking to develop drugs in the neurodegenerative space should assess the potential for licensing AU2003254590 from The University of Queensland.
- Freedom-to-Operate Analysis: Any company developing a compound for neurodegenerative diseases should conduct a thorough freedom-to-operate (FTO) analysis to identify potential infringements with AU2003254590 and other related patents.
- Pipeline Development: For The University of Queensland, understanding the competitive landscape is crucial for strategic decisions regarding further development, licensing, or enforcement of their patent rights.
- Investment Due Diligence: Investors evaluating companies in the neurodegenerative therapeutic area must scrutinize the patent protection, including this patent and any related filings, to assess market exclusivity and potential litigation risks.
Key Takeaways
AU2003254590 protects a specific class of compounds and their use in treating neurodegenerative diseases. The patent grants exclusivity to The University of Queensland until October 23, 2023. The broad claims related to the compound structure and therapeutic application necessitate careful consideration for any entity operating within this therapeutic area. Understanding the full scope of the claims, especially the definitions of Formula I and Formula II and the range of substituents, is critical for both asserting and navigating around this patent.
Frequently Asked Questions
-
When does AU2003254590 expire?
AU2003254590 is expected to expire on October 23, 2023.
-
What therapeutic area does AU2003254590 cover?
The patent covers the treatment of neurodegenerative diseases.
-
Can a generic version of the drug be launched before the patent expiry?
Launching a generic version before patent expiry would constitute infringement unless specific licenses or valid legal challenges to the patent are in place.
-
Does AU2003254590 protect the manufacturing process of the compound?
The patent claims may include methods of synthesis, providing protection for specific manufacturing processes. A detailed review of all claims is required to confirm this.
-
Who is the current owner of AU2003254590?
The University of Queensland is the assignee of AU2003254590.
Citations
[1] The University of Queensland. (2004). Australian Patent AU2003254590. https://pericles.ipaustralia.gov.au/ols/home (Accessed on [Current Date])
